Emerging biomarkers in cognition

Meredith Wicklund, Ronald C. Petersen

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.

Original languageEnglish (US)
Pages (from-to)809-828
Number of pages20
JournalClinics in Geriatric Medicine
Issue number4
StatePublished - Nov 2013


  • Alzheimer disease
  • Biomarkers
  • Dementia

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Emerging biomarkers in cognition'. Together they form a unique fingerprint.

Cite this